The interpretation of long-acting cabotegravir and rilpivirine concentrations is complicated by the lack of consensus on the threshold to consider. Building on real-world therapeutic drug monitoring data and documented virologic failures, this article provides a reappraisal of the existing thresholds and guidance for the interpretation of cabotegravir and rilpivirine concentrations.
No takes yet. Share an insight, caveat, or question.
Thoueille et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: